Navigation Links
DrugRisk Updates with Latest Case Numbers Since Januvia Lawsuits Sent to MDL Court
Date:9/24/2013

New York, NY (PRWEB) September 24, 2013

The diabetes drug safety center at DrugRisk.com is announcing new information on the site for patients taking the medications Januvia or Janumet. A federal multidistrict litigation court recently created to handle lawsuits alleging the drugs caused pancreatic cancer has issued the latest update on case volumes*.

DrugRisk is a resource center created to improve patient safety by giving those taking popular prescription drugs the latest warnings, recalls, studies and legal news. Visitors can see if others are experiencing similar side effects and decide if they need legal advice.

Januvia and Janumet are popular oral diabetes medications prescribed to those with type-2 diabetes, taken twice a day to lower blood sugar levels. In recent years, they have been the best-selling drugs for pharmaceutical company Merck**.

However, DrugRisk has added studies warning of a risk of Januvia cancer. In 2011, researchers from UCLA discovered subjects given Januvia had an increased risk of developing pancreatic cancer and thyroid cancer***. The American Medical Association recently advised diabetes drugs like these can double the risk of pancreatitis, a major risk factor for pancreatic cancer****.

Due to the number of patients who have filed a Januvia lawsuit alleging cancer, cases have been consolidated to a special federal multidistrict litigation court. (In Re: Incretin-Based Therapies Products Liability Litigation, MDL 2452, Southern District of California).

Now, the latest records from the court show 60 people have already filed a Januvia lawsuit or similar action relating to Byetta, Janumet or Victoza*.

Anyone affected by cancer after taking Januvia or Janumet is encouraged to speak with a lawyer about their legal options. However, due to the specialized nature of federal drug injury cases,

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related medicine news :

1. DrugRisk Update: Byetta Lawsuits Headed to Special Federal Court
2. DrugRisk Update: Januvia Lawsuits Alleging Cancer Headed to Federal Court
3. DrugRisk Update: Latest Court Order Moves Mirena Lawsuits Forward
4. DrugRisk News: Court Consolidates Januvia Lawsuits Alleging Cancer
5. DrugRisk Update: Court Issues Latest Decision in Pradaxa Bleeding Litigation
6. DrugRisk Update: New Study Warns of Pradaxa Dangers as Lawsuits Increase
7. DrugRisk Update: Panel To Decide Fate of Januvia Lawsuits Next Week
8. DrugRisk Announces Latest Ruling By Judicial Panel on NuvaRing Lawsuits
9. DrugRisk Announces Drop in Yaz Lawsuits As Bayer Commits $1.5 Billion to Settlements
10. DrugRisks Announces Yaz Center With Latest Updates on Blood Clot Warnings and Settlements
11. DrugRisks Update: New Study Warns of Pradaxa Brain Bleeding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... ... August 31, 2015 , ... Jvion, the ... latest predictive use case focused on helping hospital perform under the Center for ... hospital payments are adjusted based on performance across four domains related to care ...
(Date:8/31/2015)... ... August 31, 2015 , ... ITC Global Translations ... information for specific translation services within the medical and pharmaceutical industries. These are ... of successful work. , ITC Global Translations specializes in professional translation services for ...
(Date:8/31/2015)... CA (PRWEB) , ... August 31, 2015 , ... When it comes to undergoing a ... the top of the head. Adding more volume to the hair on top of ... for patients who have a good amount of donor hair on other areas of their ...
(Date:8/31/2015)... ... 31, 2015 , ... Wound Care Advantage, a leader in ... to Hyperbaric Medicine Course. The next UHMS approved 40-hour Introduction to Hyperbaric Medicine ... Long Beach, CA. The meeting is open for registration from physicians, clinicians and ...
(Date:8/31/2015)... ... 31, 2015 , ... The 2015 New York Regional ... family members, medical professionals, and researchers, covering a variety of topics related to ... collaborative effort between the Mesothelioma Applied Research Foundation and Memorial Sloan ...
Breaking Medicine News(10 mins):Health News:Jvion Releases Value-Based Purchasing Predictive Use Case 2Health News:GoMarketing Announces Major Updates to ITC Global Translations Website http://www.ITCGlobalTranslations.com 2Health News:GoMarketing Announces Major Updates to ITC Global Translations Website http://www.ITCGlobalTranslations.com 3Health News:Body Hair Transplants to Help Achieve a Full Head of Hair 2Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 2Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 3Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 4Health News:New York Experts on Mesothelioma Come Together at Memorial Sloan Kettering Cancer Center 2Health News:New York Experts on Mesothelioma Come Together at Memorial Sloan Kettering Cancer Center 3
... DUBLIN, Ohio, Feb. 17 Cardinal Health today,announced it ... (FDA),on an amended consent decree regarding the company,s infusion ... has operated under a consent decree since February 2007,for ... implementing a new,quality system on April 2, 2008. Under ...
... too much TV is linked to poorer recall, study finds ... such as reading or playing games, in middle age and ... new research. , The study included 197 people, ages 70 ... and 1,124 people in the same age group with no ...
... Fla. Vitamin supplements can prevent hearing loss in ... one step closer to the development of a pill ... hearing loss in humans. , The findings will be ... annual conference in Baltimore by senior author Colleen Le ...
... INDIANAPOLIS, Feb. 17 WellPoint, Inc.,(NYSE: WLP ... webcast of its,Investor Conference on Tuesday, February 24, 2009. ... and chief executive officer of WellPoint, Inc.,and will feature ... The event is scheduled to ...
... 23 PERCENTSAN DIEGO, Feb. 17 Volcano Corporation (Nasdaq: ... manufacturing and sales of products for the diagnosis and ... that revenues for the full year 2008 increased 31 ... the fourth quarter of 2008 increased 23 percent over ...
... declines of up to 70 percent, CDC researchers say, ... caused by methicillin-resistant Staphylococcus aureus (MRSA) have ... the U.S. Centers for Disease Control and Prevention report. ... to certain antibiotics, can cause severe infections in people ...
Cached Medicine News:Health News:Cardinal Health, FDA Amend Infusion Pump Consent Decree 2Health News:Reading, Games Help Keep Aging Memories Sharp 2Health News:Vitamin supplements may protect against noise-induced hearing loss 2Health News:Vitamin supplements may protect against noise-induced hearing loss 3Health News:WellPoint Announces Webcast of its Conference with Investment Community 2Health News:Volcano Reports Full Year Revenues Increase 31 Percent 2Health News:Volcano Reports Full Year Revenues Increase 31 Percent 3Health News:Volcano Reports Full Year Revenues Increase 31 Percent 4Health News:Volcano Reports Full Year Revenues Increase 31 Percent 5Health News:Volcano Reports Full Year Revenues Increase 31 Percent 6Health News:Volcano Reports Full Year Revenues Increase 31 Percent 7Health News:Volcano Reports Full Year Revenues Increase 31 Percent 8Health News:Volcano Reports Full Year Revenues Increase 31 Percent 9Health News:Volcano Reports Full Year Revenues Increase 31 Percent 10Health News:Volcano Reports Full Year Revenues Increase 31 Percent 11Health News:Volcano Reports Full Year Revenues Increase 31 Percent 12Health News:Volcano Reports Full Year Revenues Increase 31 Percent 13Health News:Volcano Reports Full Year Revenues Increase 31 Percent 14Health News:MRSA Cases Dropping in Hospital ICUs 2Health News:MRSA Cases Dropping in Hospital ICUs 3Health News:MRSA Cases Dropping in Hospital ICUs 4
(Date:8/31/2015)... 31, 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: ... field of regenerative medicine, today announced that the ... Chicago -based Rush University Medical Center in ... escalating doses of AST-OPC1 (oligodendrocyte progenitor cells) in ... cervical spinal cord injury (SCI). This represents the ...
(Date:8/31/2015)... 2015   BioLife Solutions , Inc. (NASDAQ: ... marketer of proprietary clinical grade cell and tissue ... media and a related cloud hosted ... smart shippers ("BioLife" or the "Company"), today ... biopharmaceutical company focused on developing and commercializing novel ...
(Date:8/28/2015)... , Aug. 28, 2015  With the heroin ... reaching deadlier heights, Jacksonville -based Lakeview ... Hemphill is helping to explain why fentanyl is ... approximately 40 to 50 times more potent than pharmaceutical ... users as heroin, the risk of death skyrockets. ...
Breaking Medicine Technology:Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 2BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 3BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 4BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 5Lakeview Health's Dr. Philip Hemphill Explains Why Heroin Addicts Are Now Dying of Fentanyl Overdoses 2
... (OTCQX: DATA), a technology and services company focused on global ... its Vice President of Research and Development, Chris Wilke, has ... 2009 Society for Clinical Data Management (SCDM) Annual Conference which ... Mr. Wilke will be discussing Is 100% EDC Realistic? ...
... ThermalTherapeutic Systems, Inc., developers of a highly ... today the completion of $2.75 Million Series A ... funding by the Pittsburgh Life Sciences Greenhouse, and ... investments by the Pittsburgh Life Sciences Greenhouse and ...
Cached Medicine Technology:DATATRAK to Present at 2009 SCDM Annual Conference 2DATATRAK to Present at 2009 SCDM Annual Conference 3ThermalTherapeutic Systems Completes $2.75 Million Series A Financing With Originate Ventures 2
The Natural Selection family of specialty allografts is spinal concepts response to surgeon requests for spinal allograft devices to eliminate the need for painful autograft harvesting....
Transcranial vascular DWL doppler....
Transcranial vascular DWL doppler....
... Neurocare is a full-featured physiologic testing system offered ... contains many of the features of our flagship ... economical price. , ,The smaller size of the ... environment, the physician's office, a mobile service or ...
Medicine Products: